

RESEARCH MONOGRAPH . COMPOUND PROFILE

Somatropin

A 191-amino acid recombinant polypeptide identical to endogenous pituitary-derived 22 kDa human growth hormone, produced by recombinant DNA technology in Escherichia coli or Saccharomyces cerevisiae, indicated for growth hormone deficiency across pediatric and adult populations and distinguished from earlier pituitary-extracted preparations by the elimination of prion contamination risk and by the capacity for unlimited supply.

DOCUMENT	KDC-MN-1382
ISSUED	2026-05-10
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Recombinant human growth hormone (191-amino acid single-chain polypeptide, identical to endogenous pituitary 22 kDa growth hormone)

RESEARCH USE ONLY

ABSTRACT

Somatropin is the International Nonproprietary Name for recombinant human growth hormone (rhGH), a 191-amino acid, single-chain, non-glycosylated polypeptide with a molecular weight of 22,124 daltons that is identical in primary sequence to the major circulating isoform of endogenous pituitary growth hormone encoded by the GH1 gene on chromosome 17q23.3. The compound was first produced by recombinant DNA technology at Genentech, Inc., where Goeddel et al. (1979) achieved direct expression of the human GH coding sequence in *Escherichia coli* [1], leading to the FDA approval of somatrem (methionyl-hGH, Protropin) in 1985 and of somatropin (authentic 191-amino acid sequence, Humatrope) in 1987. The transition from cadaveric pituitary-extracted growth hormone to recombinant production was driven by the identification in 1985 of Creutzfeldt-Jakob disease cases in recipients of pituitary-derived GH, a transmissible spongiform encephalopathy that resulted in the withdrawal of all pituitary-derived GH preparations worldwide [2, 3]. Somatropin acts through the growth hormone receptor (GHR), a single-pass transmembrane receptor of the type I cytokine receptor superfamily. Ligand binding induces receptor dimerization and rotational activation, transphosphorylation of the receptor-associated tyrosine kinase Janus kinase 2 (JAK2), and downstream activation of signal transducer and activator of transcription 5b (STAT5b), the mitogen-activated protein kinase (MAPK/ERK) cascade, and the phosphatidylinositol 3-kinase/Akt pathway [4, 5]. The dominant endocrine mediator of the growth-promoting action of somatropin is insulin-like growth factor 1 (IGF-1), synthesized principally in the liver in response to GH receptor

activation and acting through the IGF-1 receptor on growth plate chondrocytes, skeletal muscle, and other target tissues [6]. Pharmacokinetics after subcutaneous injection are characterized by an absorption half-life of approximately 2 to 3 hours, a peak plasma concentration at 3 to 6 hours, a systemic bioavailability of approximately 70 to 80 percent, a volume of distribution approximating plasma volume (approximately 50 mL/kg), and an elimination half-life of 3 to 5 hours driven predominantly by renal and hepatic receptor-mediated clearance [7, 8]. Approved indications in the United States and the European Union include pediatric growth hormone deficiency, Turner syndrome, chronic renal insufficiency prior to transplantation, Prader-Willi syndrome, children born small for gestational age who fail to demonstrate catch-up growth, idiopathic short stature, SHOX gene haploinsufficiency, Noonan syndrome, adult growth hormone deficiency, and AIDS-associated wasting and cachexia [9, 10]. The compound is administered by daily subcutaneous injection at weight-based doses typically in the range of 0.024 to 0.067 mg/kg/day in pediatric indications and 0.1 to 0.8 mg/day (non-weight-based) in adult GH deficiency, with dose titration guided by serum IGF-1 concentration [10, 11]. Long-acting formulations including somapacitan (Sogroya, weekly subcutaneous) and lonapegsomatropin (Skytrofa, weekly subcutaneous) have been approved since 2020 as alternatives to daily somatropin for selected indications [12, 13]. The principal adverse events are dose-dependent and include peripheral edema, arthralgia, myalgia, carpal tunnel syndrome, and insulin resistance, all attributable to the physiological actions of growth hormone on sodium retention, connective tissue, and glucose metabolism [14]. Long-term safety surveillance through multinational registries (KIGS, GeNeSIS, HypoCCS, NCGS)

encompassing more than 100,000 patient-years has not demonstrated a causal increase in de novo malignancy, recurrence of primary tumors, or cardiovascular mortality at replacement doses, though the data mandate continued vigilance in patients with active malignancy, proliferative diabetic retinopathy, or critical illness [15, 16, 17]. This monograph documents the chemistry and biosynthesis of somatropin; the growth hormone receptor signaling cascade in molecular detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology of the GH-IGF-1 axis; the clinical evidence base across all approved and investigational indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety-signal analysis; and a comparative assessment of five alternative growth-promoting or GH-axis compounds against somatropin on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Somatropin.

Marketed names: Genotropin (Pfizer), Humatrope (Eli Lilly), Norditropin (Novo Nordisk), Saizen (Merck Serono), Omnitrope (Sandoz, the first biosimilar rhGH approved in the United States and European Union), Nutropin AQ (Genentech/Roche), Zomacton (Ferring), Serostim (EMD Serono, approved for AIDS wasting), Zorbtive (EMD Serono, approved for short bowel syndrome), and multiple additional biosimilar and generic preparations marketed outside the United States and European Union.

Development codes: The original Genentech expression product was designated methionyl-hGH (met-hGH, somatrem) owing to an additional N-terminal methionine residue retained from the bacterial expression system. Somatrem was marketed as Protropin (FDA approval October 1985). The authentic 191-amino acid product without the methionine extension was subsequently designated somatropin and was first marketed as Humatrope (FDA approval March 1987) [1, 18].

Chemical Abstracts Service registry numbers: 12629-01-5 (human growth hormone, generic); 98581-34-7 (somatropin, recombinant). The CAS number 79818-96-7 applies to somatrem (methionyl-hGH, 192-amino acid form).

International Union of Pure and Applied Chemistry name: Not applicable (polypeptide). The compound is defined by its primary amino acid sequence of 191 residues, two intramolecular disulfide bonds (Cys53-Cys165 and Cys182-Cys189), and identity to the GH1 gene product.

Pharmacopoeial designation: The United States Pharmacopeia and the European Pharmacopoeia each maintain monographs for somatropin concentrated solution and somatropin for injection, specifying identity, purity, potency (bioassay), and related substances.

1.2 Structural class and chemistry

Somatropin is a single-chain, non-glycosylated polypeptide hormone of 191 amino acid residues with a molecular weight of 22,124 daltons. The protein adopts a four-helix bundle topology characteristic of the class I helical cytokine superfamily, with helices designated H1 through H4 connected by loop regions. The two intramolecular disulfide bonds (Cys53-Cys165, large loop; Cys182-Cys189, small loop near the C-terminus) are essential for biological activity and for maintenance of the native three-dimensional structure [19, 20].

Molecular formula: C₉₉₀H₁₅₂₈N₂₆₂O₃₀₀S₇ (monoisotopic mass 22,124 Da).

Isoelectric point: Approximately 5.27.

Physical properties: White to off-white lyophilized powder when supplied as a lyophilisate for reconstitution. Soluble in water and in dilute acid; the compound is a polypeptide and is denatured by organic solvents, extremes of pH, and elevated temperatures. Stability of the reconstituted solution is temperature-dependent; the compound is stable at 2 to 8 degrees Celsius for 14 to 28 days after reconstitution depending on the formulation and excipient composition.

Isoforms and variants: The GH1 gene produces multiple mRNA splice variants. The dominant circulating isoform is the 22 kDa form (191 amino acids), which is the form produced by all recombinant somatropin products. A 20 kDa splice variant (missing residues 32 through 46) constitutes approximately 5 to 10 percent of pituitary secretion and has distinct receptor-binding and metabolic properties but is not produced by any approved recombinant product [21]. Investigators should be aware that endogenous GH is a mixture of isoforms whereas recombinant somatropin is a single molecular species; pharmacodynamic differences between endogenous pulsatile GH secretion and exogenous subcutaneous somatropin are attributable in part to this distinction.

1.3 Synthesis (biosynthesis and manufacturing)

Somatropin is produced by recombinant DNA technology. The coding sequence for the mature 191-amino acid human growth hormone (without the 26-amino acid signal peptide) is inserted into a bacterial expression vector and expressed in *Escherichia coli* (the production system used by Genentech, Eli Lilly, Pfizer, Sandoz, and most manufacturers) or in *Saccharomyces cerevisiae* (the yeast-based system used by Novo Nordisk for Norditropin). The bacterial expression system

produces somatropin as intracellular inclusion bodies that require solubilization in chaotropic agents (urea, guanidinium chloride), refolding under controlled redox conditions to form the native disulfide bonds, and purification by multiple chromatographic steps including ion-exchange chromatography, hydrophobic interaction chromatography, and size-exclusion chromatography [1, 22].

The yeast expression system secretes somatropin into the culture medium in a correctly folded, soluble form, simplifying downstream processing. The final product from either system is a monomeric polypeptide of 191 residues with correct disulfide bonding, confirmed by peptide mapping, mass spectrometry, circular dichroism spectroscopy, and bioassay.

The manufacturing process is subject to stringent regulatory oversight. Each lot is characterized for identity (N-terminal sequencing, peptide mapping), purity (reversed-phase HPLC, size-exclusion HPLC, capillary electrophoresis), potency (Nb2 cell proliferation bioassay or equivalent), endotoxin content, host cell protein, host cell DNA, and aggregation. Somatropin is a biologic; lot-to-lot variability is inherent in biologic manufacturing and is controlled within pharmacopoeial specifications [22].

2. Abstract

Somatropin is recombinant human growth hormone (rhGH), a 191-amino acid polypeptide identical to the major 22 kDa isoform of endogenous pituitary growth hormone, produced by recombinant DNA technology and approved worldwide for the treatment of growth failure and metabolic derangements caused by growth hormone deficiency and related conditions. The compound was among the earliest products of the recombinant DNA revolution: the Goeddel et al. (1979) expression of the human GH gene in *E. coli* at Genentech was a landmark in biotechnology [1], and the subsequent FDA approval of somatrem in 1985 and somatropin in 1987 established the first recombinant hormone replacement therapies.

The clinical need for recombinant production was made urgent by the 1985 identification of iatrogenic Creutzfeldt-Jakob disease in young adults who had received pituitary-derived human growth hormone during childhood, a prion-contamination crisis that resulted in the permanent withdrawal of all cadaveric GH preparations [2, 3]. Between 1963 and 1985, pituitary-derived GH was the only available treatment for growth hormone deficiency, and supply was severely limited by the number of cadaveric pituitary glands available for extraction. The recombinant product eliminated both the contamination risk and the supply constraint.

The mechanism of action of somatropin is the physiological growth hormone signaling cascade. Growth hormone binds the extracellular domain of the growth hormone receptor (GHR) at two asymmetric binding sites (Site 1 and Site 2), inducing receptor dimerization and a conformational change that activates the receptor-associated JAK2 tyrosine kinase [4, 5]. JAK2 phosphorylation activates STAT5b (the principal transcription factor mediating GH-dependent gene expression in liver, including IGF-1, IGFBP-3, and the acid-labile subunit), the MAPK/ERK pathway (mediating proliferative responses), and the PI3K/Akt pathway (mediating metabolic and anti-apoptotic responses) [5, 23]. The dominant endocrine effector of the growth-promoting action is IGF-1, which circulates in a ternary complex with IGFBP-3 and the acid-labile subunit and acts on growth plate chondrocytes to drive linear bone growth [6].

Current approved indications span pediatric growth hormone deficiency, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, small for gestational age without catch-up growth, idiopathic short stature, SHOX deficiency, Noonan syndrome, adult growth hormone deficiency, AIDS wasting, and short bowel syndrome [9, 10]. The compound has also been used off-label and in research settings for age-related decline in GH secretion, body composition optimization, wound healing, and sports performance enhancement, the last of which is prohibited by the World Anti-Doping Agency [24].

Administration is by daily subcutaneous injection at individualized weight-based or non-weight-based doses, titrated to serum IGF-1 levels within the age- and sex-adjusted normal range. Weekly long-acting formulations (somapacitan, long-acting somatotropin) have expanded treatment options since 2020 [12, 13].

The safety profile at replacement doses is favorable. Principal adverse events are dose-dependent peripheral edema, arthralgia, carpal tunnel syndrome, and insulin resistance [14]. Long-term registry surveillance has not demonstrated a causal increase in malignancy or cardiovascular mortality at physiological replacement doses, though active malignancy and critical illness remain contraindications [15, 16, 17].

3. Discovery and Development History

3.1 Isolation and characterization of pituitary growth hormone

Human growth hormone was first isolated from cadaveric pituitary glands by Li and Papkoff at the University of California, Berkeley, in 1956 [25]. The amino acid sequence was determined by Li and colleagues over the following decade. The protein was characterized as a 191-amino acid single-chain polypeptide with two disulfide bonds and species-specific biological activity (primate GH, but not bovine or porcine GH, is active in humans, a species restriction attributable to differences in GH receptor binding specificity).

3.2 Pituitary-derived growth hormone therapy (1958 to 1985)

The first therapeutic administration of pituitary-derived human growth hormone to a GH-deficient child was reported by Raben in 1958 [26]. Between 1963 and 1985, pituitary-derived GH (extracted from cadaveric pituitaries collected at autopsy) was the only treatment available for pediatric growth hormone deficiency. The supply was chronically inadequate; in the United States, the National Hormone and Pituitary Program (NHPP) coordinated collection and distribution and allocated limited supplies on the basis of clinical severity. Doses were typically 0.1 mg/kg three times per week, substantially lower than modern daily dosing, driven by supply constraints rather than pharmacological optimization.

3.3 The Creutzfeldt-Jakob disease crisis

In April 1985, the Centers for Disease Control reported the first case of Creutzfeldt-Jakob disease (CJD) in a young adult who had received pituitary-derived GH during childhood [2]. Within months, additional cases were identified in the United States, the United Kingdom, France, and other countries. The association was causal: the prion agent responsible for CJD had contaminated batches of pituitary-derived GH during the extraction process, and the purification methods in use at the time (acid-acetone extraction) were insufficient to inactivate the protease-resistant prion pro-

tein. The NHPP immediately suspended distribution in April 1985. Ultimately, more than 200 cases of iatrogenic CJD were attributed to pituitary-derived GH worldwide, with an incubation period ranging from 5 to more than 30 years [3]. The crisis permanently ended the pituitary-derived GH era and established the medical, ethical, and regulatory imperative for recombinant production.

3.4 Recombinant production at Genentech

The recombinant expression of human growth hormone was achieved at Genentech, Inc., by Goeddel, Heyneker, and colleagues, who reported in 1979 the direct expression of a synthetic gene encoding the mature 191-amino acid human GH in *E. coli* [1]. The initial bacterial product retained an N-terminal methionine residue (met-hGH, later designated somatrem) because bacterial ribosomes initiate translation with formylmethionine and the signal peptidase processing that removes the initiator methionine was incomplete for this construct. Somatrem was approved by the FDA in October 1985 as Protropin, making it the first recombinant hormone approved for therapeutic use and the second recombinant pharmaceutical product after recombinant insulin (Humulin, approved 1982).

The 192-amino acid met-hGH (somatrem) differed from endogenous GH by the single N-terminal methionine and was associated with the development of anti-GH antibodies in a fraction of patients, though these antibodies were generally non-neutralizing and did not compromise clinical efficacy [27]. Eli Lilly subsequently developed and obtained FDA approval in March 1987 for somatropin (Humatrope), the authentic 191-amino acid product without the N-terminal methionine, produced using an *E. coli* expression system with an engineered signal peptide that directed secretion and removal of the initiator methionine [18]. Somatropin became the reference standard for all subsequent rhGH products, and somatrem was withdrawn from the market in 2004.

3.5 Expansion of indications and biosimilar development

Between 1987 and 2010, the approved indications for somatropin expanded substantially beyond pediatric GH deficiency to encompass Turner syndrome (1996), chronic renal insufficiency (1993), Prader-Willi syndrome (2000), small for gestational age (2001), idiopathic short stature (2003), adult GH deficiency (1996), AIDS wasting (1996, Serostim), and short bowel syndrome (2003, Zorbtive) [9, 10]. The ex-

pansion reflected both clinical investigation of the broad physiological roles of GH and the commercial interest of multiple manufacturers in the growing rhGH market.

The first biosimilar somatropin, Omnitrope (Sandoz), was approved in the European Union in 2006 and in the United States in 2006, making it among the first biosimilar biologic products approved in either jurisdiction [28]. Multiple additional biosimilar somatropin products have been approved worldwide since 2006.

3.6 Long-acting formulations

The inconvenience and compliance burden of daily subcutaneous injection drove development of long-acting GH formulations. Somapacitan (Sogroya, Novo Nordisk), a GH analog with an albumin-binding fatty acid side chain that extends the elimination half-life to approximately 2 to 3 days, was approved by the FDA in August 2020 for adult GH deficiency and in 2023 for pediatric GH deficiency [12]. Lonapegsomatropin (Skytrofa, Ascendis Pharma), a transient PEGylated GH pro-drug that releases unmodified somatropin through hydrolysis of a cleavable linker, was approved by the FDA in August 2021 for pediatric GH deficiency [13]. Both products are administered by weekly subcutaneous injection and have demonstrated non-inferiority to daily somatropin in pivotal clinical trials.

4. Mechanism of Action

4.1 Growth hormone receptor binding and activation

Somatropin exerts its biological effects through the growth hormone receptor (GHR), a 620-amino acid single-pass type I transmembrane glycoprotein belonging to the class 1 cytokine receptor superfamily. The GHR exists as a preformed, inactive homodimer on the cell surface [29]. Growth hormone binds the extracellular domain of the GHR at two distinct binding sites: Site 1 (high affinity, involving helix 4, the A-B loop, and the mini-helix of GH) engages the first GHR monomer, and Site 2 (lower affinity, involving helix 1 and helix 3 of GH) engages the second GHR monomer [4]. Sequential engagement of Site 1 and Site 2 induces a conformational rotation and repositioning of the intracellular domains that activates the receptor-associated tyrosine kinase JAK2.

The GHR does not possess intrinsic kinase activity. Signal transduction depends entirely on the constitutively associated JAK2, which is bound to the proline-rich Box 1 motif of the GHR intracellular domain [30]. Upon receptor activation, JAK2 undergoes transphosphorylation on activation loop tyrosines (Tyr1007, Tyr1008), achieving full kinase activity. Activated JAK2 then phosphorylates multiple tyrosine residues on the GHR intracellular domain, creating docking sites for SH2-domain-containing signaling molecules.

4.2 Downstream signaling cascades

Three principal signaling cascades are activated downstream of the GHR-JAK2 complex:

STAT5b pathway: The transcription factor STAT5b is recruited to phosphorylated tyrosine residues on the GHR intracellular domain, is phosphorylated by JAK2 on Tyr699, dimerizes through reciprocal SH2-phosphotyrosine interactions, translocates to the nucleus, and activates transcription of GH-responsive genes [5, 23]. The STAT5b pathway is the dominant mediator of the growth-promoting and metabolic actions of GH, as demonstrated by the severe growth failure phenotype of STAT5b loss-of-function mutations in humans [31]. Principal STAT5b target genes include

IGF-1, IGFBP-3, the acid-labile subunit (ALS), SOCS2 (a negative feedback regulator), and P450 enzymes that mediate the sexually dimorphic pattern of hepatic drug metabolism.

MAPK/ERK pathway: GH-JAK2 signaling activates the Ras-Raf-MEK-ERK cascade through the adapter proteins SHC and Grb2, leading to activation of transcription factors including Elk1 and c-Fos [5]. The MAPK pathway mediates proliferative and mitogenic responses to GH and is the principal pathway implicated in the theoretical concern about GH and malignancy risk.

PI3K/Akt pathway: GH-JAK2 signaling activates phosphatidylinositol 3-kinase (PI3K) through the insulin receptor substrate (IRS) family of adapter proteins, leading to Akt/protein kinase B activation [5]. The PI3K/Akt pathway mediates the metabolic effects of GH including glucose uptake regulation, lipid metabolism, and anti-apoptotic signaling. The insulin-antagonistic (diabetogenic) action of GH at supra-physiological concentrations is mediated in part through PI3K pathway cross-talk with insulin signaling.

4.3 The GH-IGF-1 axis

The dominant endocrine mediator of the growth-promoting action of somatropin is insulin-like growth factor 1 (IGF-1), a 70-amino acid polypeptide synthesized principally in the liver in response to GH receptor activation via STAT5b-dependent transcription [6]. IGF-1 circulates in a ternary complex with IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS), both of which are also GH-dependent gene products. The ternary complex extends the circulating half-life of IGF-1 from approximately 10 minutes (free) to approximately 12 to 16 hours and serves as a circulating reservoir of IGF-1.

IGF-1 acts through the IGF-1 receptor (IGF-1R), a heterotetrameric receptor tyrosine kinase structurally homologous to the insulin receptor, on growth plate chondrocytes, osteoblasts, skeletal muscle, and other target tissues. At the growth plate, IGF-1 stimulates chondrocyte proliferation and hypertrophy in the proliferative and hypertrophic zones, driving linear bone elongation. The dual effector hypothesis proposes that GH acts directly on growth plate stem cells to recruit them into the proliferative pool, while IGF-1 (both circulating and locally produced) drives the subsequent clonal expansion and hypertrophy [32].

4.4 Direct actions of growth hormone

In addition to the IGF-1-mediated endocrine actions, somatropin exerts direct (IGF-1-independent) metabolic actions. These include acute insulin-like effects (transient stimulation of glucose uptake in the first 1 to 2 hours after injection), followed by sustained anti-insulin effects (lipolysis stimulation, fatty acid mobilization, hepatic glucose output increase, reduction in peripheral glucose uptake) that dominate in the fasting and postprandial states [33]. The lipolytic action of GH is mediated through direct GHR activation on adipocytes, activation of hormone-sensitive lipase, and suppression of lipoprotein lipase. The net metabolic effect of chronic GH replacement at physiological doses is a shift from fat storage toward fat oxidation, increased lean body mass, and a modest increase in insulin resistance.

4.5 Negative regulation

GH signaling is subject to multiple negative feedback mechanisms. The suppressors of cytokine signaling (SOCS) family, particularly SOCS2, are induced by GH-STAT5b signaling and act to inhibit JAK2 kinase activity and to target the GHR for proteasomal degradation [34]. The protein tyrosine phosphatases SHP-1 and SHP-2 dephosphorylate JAK2 and the GHR. The pulsatile pattern of endogenous GH secretion (with intermittent peaks separated by trough periods of undetectable GH) is essential for maintaining receptor sensitivity; continuous GH exposure downregulates GHR expression and desensitizes the STAT5b pathway, a phenomenon with direct implications for the pharmacodynamics of daily versus continuous GH administration [35].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Somatropin is administered by subcutaneous injection. After subcutaneous injection, the compound is absorbed from the injection site with an absorption half-life of approximately 2 to 3 hours, reaching peak plasma concentration (C_{max}) at approximately 3 to 6 hours post-injection [7, 8]. Absolute bioavailability after subcutaneous injection is approximately 70 to 80 percent, the remainder attributable to local degradation by tissue proteases at the injection site. Intramuscular injection produces similar bioavailability with a slightly faster absorption profile. Oral bioavailability is negligible owing to proteolytic degradation in the gastrointestinal tract; the compound is a polypeptide and is not orally bioavailable.

5.2 Distribution

Somatropin distributes into a volume approximating the extracellular fluid volume, with an apparent volume of distribution of approximately 50 to 70 mL/kg (approximately 3.5 to 5 liters in an adult) [7]. Plasma protein binding is mediated principally by the growth hormone binding protein (GHBP), which is the proteolytically cleaved extracellular domain of the GHR and circulates at concentrations of approximately 10 to 50 percent of total GH-binding capacity. Approximately 40 to 50 percent of circulating GH is bound to GHBP; the remainder circulates as free hormone [36]. The GHBP-bound fraction serves as a circulating reservoir that modulates GH half-life and buffering.

5.3 Metabolism and elimination

Somatropin is cleared from the circulation by multiple mechanisms. The dominant clearance pathway is receptor-mediated endocytosis through the GHR in liver, kidney, and other GHR-expressing tissues [37]. Following receptor-mediated internalization, the GH-GHR complex is routed to lysosomes for proteolytic degradation. Renal filtration and degradation contribute approximately 20 to 30 percent of total

clearance; the kidney filters the 22 kDa monomer at the glomerulus and degrades it in proximal tubular cells. Hepatic metabolism (proteolysis, not cytochrome P450-mediated) accounts for the majority of the remainder.

The plasma elimination half-life after subcutaneous injection is approximately 3 to 5 hours in adults and in children, reflecting the composite of absorption-rate-limited kinetics (flip-flop model) and the intrinsic clearance mechanisms [7, 8]. Intravenous bolus injection produces a shorter apparent half-life of approximately 20 to 30 minutes, reflecting the rapid distribution and receptor-mediated clearance unmasked by the absence of absorption-rate limitation.

Total body clearance is approximately 2.5 to 3.5 mL/kg/min. Clearance is higher in children than in adults on a weight-adjusted basis, consistent with higher GHR density and metabolic rate.

5.4 Special populations

Renal impairment reduces GH clearance and elevates circulating GH concentrations; dose adjustment is generally not required for growth-promoting indications in chronic renal insufficiency because the growth failure in this population is multifactorial and partially GH-resistant. Hepatic impairment has not been formally studied; the principal clearance mechanisms (GHR-mediated endocytosis) are expected to be reduced in severe hepatic disease.

Pediatric pharmacokinetics are broadly similar to adult pharmacokinetics on a weight-adjusted basis, with higher clearance per kilogram and correspondingly higher weight-based doses in younger children.

5.5 Routes of administration

Subcutaneous injection is the standard route for all approved indications. Injection sites include the thigh, abdomen, upper arm, and buttock, with rotation recommended to avoid lipohypertrophy. Most marketed somatropin products are supplied in multi-dose pen devices (prefilled or cartridge-based) designed for patient self-administration. Needle-free jet injection devices are available for some products. Intravenous administration is not standard for therapeutic use but has been employed in pharmacokinetic studies and in the GH stimulation test (insulin tolerance test, arginine-GHRH test) for diagnostic purposes.

6. Preclinical Pharmacology

6.1 Growth promotion

The growth-promoting activity of somatropin has been extensively characterized in hypophysectomized rat models, in which daily subcutaneous somatropin produces dose-dependent increases in body weight gain, tibial epiphyseal plate width, and organ weight [38]. The tibial line bioassay (measurement of the width of the proliferative zone of the proximal tibial growth plate after subcutaneous GH administration) is the classical *in vivo* potency assay and remains a pharmacopoeial reference method. Growth-promoting activity is dependent on the intact GH-IGF-1 axis; growth promotion is abolished in IGF-1 receptor knockout animals and is markedly attenuated in liver-specific IGF-1 knockout animals, though local (paracrine/autocrine) IGF-1 production partially compensates [39].

6.2 Metabolic actions

In animal models, somatropin produces dose-dependent lipolysis (reduction in adipose tissue mass, elevation of free fatty acids), increase in lean body mass (skeletal muscle protein synthesis), nitrogen retention, and a biphasic effect on glucose metabolism (acute insulin-like hypoglycemia followed by sustained insulin resistance) [33]. The metabolic actions are direct effects of GH on adipocytes, hepatocytes, and skeletal muscle, partially independent of IGF-1. The lipolytic action is mediated through GHR activation on adipocytes, JAK2-STAT5b signaling, and induction of hormone-sensitive lipase.

6.3 Bone metabolism

Somatropin stimulates both bone formation (osteoblast proliferation and differentiation, collagen synthesis, alkaline phosphatase activity) and bone resorption (osteoclast recruitment through indirect mechanisms including IGF-1 and RANKL), with the net effect being a positive bone remodeling balance in GH-deficient states [40]. In animal models of GH deficiency, somatropin replacement normalizes bone mineral density, cortical thickness, and biomechanical strength.

6.4 Immunomodulation

Growth hormone has immunomodulatory properties that have been characterized in animal models and in vitro systems. GHR is expressed on T cells, B cells, natural killer cells, and macrophages. GH promotes thymic growth and T-cell development, enhances natural killer cell activity, and modulates cytokine production [41]. These immunomodulatory properties are the basis for investigational interest in GH for immune reconstitution, thymic regeneration, and age-related immunosenescence.

6.5 Cardiac and vascular effects

In animal models, GH and IGF-1 have direct effects on the myocardium, including stimulation of cardiomyocyte growth, enhancement of contractility through increased calcium handling, and promotion of angiogenesis [42]. GH deficiency in animal models is associated with reduced cardiac output, increased peripheral vascular resistance, and premature atherosclerosis; GH replacement normalizes these parameters. These preclinical findings correspond to the clinical observation that adult GH deficiency is associated with increased cardiovascular risk and that GH replacement improves cardiac structure and function.

7. Clinical Evidence Base

7.1 Pediatric growth hormone deficiency

Pediatric GH deficiency is the original and best-characterized indication for somatropin. The KIGS (Kabi International Growth Study, subsequently Pfizer International Growth Database) registry, the largest post-marketing surveillance database for rhGH, has enrolled more than 83,000 patients since 1987 and has documented average gains in adult height of 1.0 to 1.5 standard deviation scores (approximately 6 to 10 cm) above predicted untreated adult height in GH-deficient children treated with daily somatropin at doses of 0.025 to 0.050 mg/kg/day [15, 43]. Response is positively correlated with younger age at treatment initiation, greater severity of GH deficiency, higher GH dose, and longer duration of treatment. The Genentech National Cooperative Growth Study (NCGS) independently confirmed these findings in a cohort of more than 54,000 patients [44].

7.2 Turner syndrome

Somatropin at doses of 0.045 to 0.067 mg/kg/day (higher than standard GH deficiency doses, reflecting partial GH resistance in Turner syndrome) produces average adult height gains of approximately 5 to 8 cm above predicted untreated height in Turner syndrome patients [45]. Optimal response requires early initiation (before age 6 to 8 years) and combination with low-dose estrogen for pubertal induction at an age-appropriate time. The Rosenfeld et al. (1998) long-term study documented mean adult heights of 150.4 cm in optimally treated Turner syndrome patients, approximately 8.5 cm above historical untreated controls [45].

7.3 Prader-Willi syndrome

Somatropin at 0.035 mg/kg/day improves growth velocity, body composition (increased lean mass, decreased fat mass), motor development, and cognitive function in Prader-Willi syndrome [46]. The FDA approval in 2000 was based on body composition and growth velocity endpoints. Safety concerns in Prader-Willi syndrome in-

clude reports of sudden death in severely obese patients with upper airway obstruction, leading to a contraindication for somatropin in patients with severe obesity, uncontrolled respiratory infection, or upper airway obstruction [46].

7.4 Small for gestational age

Children born small for gestational age (birth weight or length below the 10th percentile for gestational age) who fail to demonstrate catch-up growth by age 2 to 4 years respond to somatropin at doses of 0.035 to 0.067 mg/kg/day, with reported adult height gains of approximately 0.6 to 1.2 SDS above untreated predicted height [47]. The higher doses used in SGA (comparable to Turner syndrome doses) reflect the relative GH resistance in this population.

7.5 Adult growth hormone deficiency

Adult GH deficiency (AGHD), whether of childhood onset persisting into adulthood or of adult onset (pituitary tumor, surgery, radiation, traumatic brain injury), is characterized by increased visceral adiposity, decreased lean body mass, reduced bone mineral density, dyslipidemia, increased cardiovascular risk, decreased exercise capacity, and impaired quality of life [10, 11]. Somatropin replacement at doses of 0.1 to 0.8 mg/day (non-weight-based, titrated to IGF-1 in the mid-normal range for age and sex) produces significant improvements in body composition, bone mineral density, lipid profile, exercise capacity, and quality-of-life scores [48, 49]. The HypoCCS (Hypopituitary Control and Complications Study) registry, enrolling more than 14,000 adult patients, has documented the safety and long-term metabolic benefits of AGHD replacement [16].

7.6 AIDS wasting and cachexia

Serostim (somatropin, EMD Serono) is approved at doses of 4 to 6 mg subcutaneously daily for AIDS-associated wasting (involuntary weight loss of more than 10 percent of body weight with chronic diarrhea or fever). The pivotal Schambelan et al. (1996) trial demonstrated significant increases in lean body mass and exercise capacity in AIDS wasting patients [50]. The indication has declined in clinical significance with the success of antiretroviral therapy in reducing the prevalence of AIDS wasting.

7.7 Short bowel syndrome

Zorbtive (somatropin, EMD Serono) is approved for the treatment of short bowel syndrome in patients receiving specialized nutritional support. GH promotes intestinal mucosal adaptation, increases villus height and crypt depth, and enhances nutrient absorption. The Byrne et al. (2005) study demonstrated that somatropin combined with glutamine and a modified diet significantly reduced parenteral nutrition requirements in short bowel syndrome patients [51].

7.8 Idiopathic short stature

Somatropin at doses of 0.037 to 0.067 mg/kg/day is approved for idiopathic short stature (height more than 2.25 SDS below the mean without identifiable etiology). The Wit et al. (2002) and Leschek et al. (2004) trials demonstrated adult height gains of approximately 3.5 to 7.5 cm with long-term treatment [52]. The indication remains controversial owing to the medicalization of normal-variant short stature and the modest average height gain relative to cost.

7.9 Investigational and off-label applications

Somatropin has been investigated for age-related GH decline (somatopause), fibromyalgia, wound healing in burns and surgical recovery, heart failure, and sports performance enhancement. The Rudman et al. (1990) study in elderly men demonstrated increased lean body mass and decreased adipose tissue mass with 6 months of GH administration [53], generating substantial interest in GH as an anti-aging therapy. However, subsequent studies demonstrated that the metabolic benefits in elderly populations are accompanied by frequent adverse events (edema, arthralgia, glucose intolerance) and no demonstrated improvement in functional outcomes or mortality, and the Endocrine Society and the American Association of Clinical Endocrinologists do not recommend GH for anti-aging purposes [54].

8. Sourcing and Quality Verification

Pharmaceutical-grade somatropin is available from multiple manufacturers as FDA-approved and EMA-approved biologic products. The principal marketed products (Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, Nutropin AQ, Zomacton) are manufactured under current Good Manufacturing Practice (cGMP) regulations and are subject to pharmacopoeial specifications for identity, purity, potency, and safety.

Research-grade recombinant human growth hormone is supplied by multiple biochemical suppliers (Sigma-Aldrich, R&D Systems, PeproTech, ProSpec, Sino Biological) at purities greater than 95 percent by SDS-PAGE and HPLC. Research-grade material is intended for in vitro and in vivo laboratory use and is not manufactured under cGMP conditions.

Investigators should confirm compound identity and quality on every lot through:

- SDS-PAGE under reducing and non-reducing conditions (single band at approximately 22 kDa)
- Reversed-phase HPLC purity assessment (area-percent purity greater than 95 percent)
- Mass spectrometry confirmation of molecular weight (22,124 +/- 5 Da for the intact protein)
- Endotoxin testing (Limulus amebocyte lysate assay, less than 1 EU per microgram for in vivo applications)
- Bioactivity confirmation (Nb2 cell proliferation assay or equivalent, specific activity greater than 2.5 IU/mg)
- Size-exclusion chromatography for aggregation assessment (monomer content greater than 95 percent)

The somatropin market includes a substantial counterfeit and substandard segment, particularly in the gray-market supply for performance enhancement. Counterfeit products may contain degraded, aggregated, or incorrectly folded pro-

tein with reduced or absent biological activity, or may contain entirely different substances. Third-party analytical testing (mass spectrometry, bioassay) is essential for any non-pharmaceutical-grade somatropin acquisition.

9. Reconstitution and Handling

Somatropin is supplied as a lyophilized powder for reconstitution (most products) or as a liquid formulation (Norditropin FlexPro, Nutropin AQ). Lyophilized products are reconstituted with the diluent provided by the manufacturer, typically bacteriostatic water for injection (containing 0.9 percent benzyl alcohol as a preservative) or sterile water for injection (for single-use vials or for neonates, in whom benzyl alcohol is contraindicated).

Reconstitution should be performed by directing the diluent stream against the glass wall of the vial rather than directly onto the lyophilized cake, and the vial should be swirled gently rather than shaken vigorously. Vigorous agitation causes protein aggregation, denaturation, and loss of biological activity. The reconstituted solution should be clear and colorless; solutions that are cloudy, discolored, or contain particulate matter should not be used.

Storage of unreconstituted (lyophilized) product is at 2 to 8 degrees Celsius (refrigerator). Reconstituted solution should be stored at 2 to 8 degrees Celsius and used within 14 to 28 days depending on the product and diluent (bacteriostatic water formulations are stable longer than sterile water formulations). Do not freeze reconstituted solution. Some liquid formulations (Norditropin FlexPro) may be stored at room temperature (up to 25 degrees Celsius) for up to 21 days after first use, per manufacturer instructions.

For research applications requiring aliquoting, single-use aliquots at the intended working concentration should be prepared in polypropylene tubes, snap-frozen in liquid nitrogen or on dry ice, and stored at minus 20 or minus 80 degrees Celsius. Repeated freeze-thaw cycles cause progressive aggregation and activity loss; limit to fewer than 3 cycles. Addition of 0.1 percent bovine serum albumin as a carrier protein reduces adsorptive losses to tube surfaces for dilute solutions (less than 100 micrograms per milliliter).

10. Stack Interactions and Combinations

Somatropin interacts with several drug classes and endogenous hormone systems through its metabolic and endocrine actions. Investigators and clinicians should consider the following interactions:

Glucocorticoids: Cortisol and synthetic glucocorticoids inhibit GH secretion and attenuate the growth-promoting effect of somatropin. Patients with multiple pituitary hormone deficiencies receiving glucocorticoid replacement should use the lowest effective hydrocortisone dose to avoid antagonism of GH action. Supraphysiological glucocorticoid exposure (iatrogenic Cushing syndrome) substantially reduces somatropin efficacy [55].

Thyroid hormones: GH increases the peripheral conversion of thyroxine (T4) to triiodothyronine (T3) through induction of type 1 deiodinase. Initiation of somatropin therapy may unmask central hypothyroidism in patients with undiagnosed hypothalamic-pituitary disease, necessitating thyroid function monitoring and levothyroxine initiation if indicated [56].

Sex steroids: Oral estrogen increases hepatic first-pass exposure and attenuates the IGF-1 response to somatropin through induction of SOCS2 and suppression of hepatic GHR signaling. Transdermal estrogen does not produce this effect because it avoids the hepatic first pass. Women receiving oral estrogen replacement may require higher somatropin doses to achieve target IGF-1 levels [57]. Androgens (testosterone, oxandrolone) are synergistic with somatropin for growth promotion and are used in combination in Turner syndrome and in constitutional delay of growth and puberty.

Insulin and oral hypoglycemics: Somatropin produces dose-dependent insulin resistance. Patients with pre-existing diabetes mellitus or glucose intolerance may require upward adjustment of insulin or oral hypoglycemic doses during somatropin therapy. Glucose monitoring is recommended during initiation and dose titration of somatropin [14].

IGF-1 (mecasermin): Concurrent administration of somatropin and mecasermin (recombinant IGF-1) is not recommended and has not been studied. The combination would produce additive IGF-1-mediated effects with unpredictable dose-response characteristics and theoretical risk of hypoglycemia and accelerated growth.

Anticonvulsants and CYP3A4 substrates: GH induces selected cytochrome P450 enzymes in a sex-dependent and STAT5b-dependent manner. GH replacement in AGHD has been reported to increase the clearance of antipyrine, cortisol, and selected CYP3A4 substrates. Drug-drug interactions are generally modest but should be considered for narrow-therapeutic-index drugs [58].

GH secretagogues (GHRP-6, ipamorelin, tesamorelin, sermorelin): Co-administration of somatropin with GH-releasing peptides or GH-releasing hormone analogs is pharmacologically redundant for the GHR activation endpoint but may be used in research to distinguish direct GH effects from GH-secretagogue-mediated pituitary effects.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events at replacement doses are dose-dependent and reflect the physiological actions of growth hormone:

- Peripheral edema (5 to 15 percent at standard replacement doses; attributable to GH-mediated sodium and water retention through direct renal tubular effects)
- Arthralgia and myalgia (5 to 15 percent; attributable to connective tissue effects and sodium retention in periarticular tissues)
- Carpal tunnel syndrome (2 to 5 percent in adults; attributable to soft tissue swelling in the carpal tunnel)
- Headache (5 to 10 percent in children; rarely indicative of intracranial hypertension, see below)
- Injection site reactions (3 to 5 percent; erythema, pain, lipoatrophy, or lipohypertrophy at the injection site)

These adverse events are generally dose-related and resolve with dose reduction. The adult GH deficiency indication uses lower doses (0.1 to 0.8 mg/day) than the earlier weight-based protocols used in clinical trials, and adverse-event rates have declined accordingly [14].

11.2 Metabolic adverse events

Insulin resistance and glucose intolerance are consistent pharmacological effects of GH. In the HypoCCS registry, the incidence of new-onset type 2 diabetes in adults receiving somatropin was approximately 2 to 3 percent per year, modestly higher than age-matched controls but confounded by the increased baseline metabolic risk associated with GH deficiency itself [16]. Glucose monitoring is recommended during treatment.

11.3 Intracranial hypertension

Benign intracranial hypertension (pseudotumor cerebri) is a rare but serious adverse event, occurring predominantly in children, with an estimated incidence of 1 in 1,000 to 1 in 10,000 treated patients [59]. Presenting symptoms include headache, visual changes, and papilledema. The mechanism is incompletely characterized but may involve GH-mediated increases in cerebrospinal fluid production. Fundoscopic examination is recommended at baseline and periodically during treatment, particularly in the first months. The condition is generally reversible with treatment discontinuation and appropriate management.

11.4 Slipped capital femoral epiphysis

Children receiving somatropin are at modestly increased risk for slipped capital femoral epiphysis (SCFE), with an estimated incidence of 56 to 73 per 100,000 treatment-years [60]. The mechanism is attributed to the rapid growth acceleration in the setting of a growth plate that may have been previously quiescent. Clinicians should evaluate children presenting with hip or knee pain, limp, or decreased hip range of motion during GH therapy.

11.5 Scoliosis progression

Existing scoliosis may progress during somatropin therapy owing to the accelerated spinal growth. The effect is not causative but is an expected consequence of growth acceleration in patients with pre-existing spinal curvature, particularly in Turner syndrome and Prader-Willi syndrome.

11.6 Malignancy risk

The relationship between somatropin therapy and malignancy risk has been extensively studied and debated. Theoretical concern arises from the mitogenic properties of GH and IGF-1 (MAPK/ERK and PI3K/Akt pathway activation). Epidemiological evidence from the SAGhE (Safety and Appropriateness of Growth hormone treatments in Europe) study initially reported increased overall mortality and increased cerebrovascular mortality in French adults who had received GH during childhood [61], but subsequent analyses from the SAGhE collaboration in Belgium, the Netherlands, and Sweden did not confirm these findings [62]. The KIGS, GeNeSIS, NCGS, and HypoCCS registries, collectively encompassing more

than 100,000 patient-years of follow-up, have not demonstrated a causal increase in de novo malignancy at replacement doses [15, 16, 17]. Current guidelines recommend against somatropin use in patients with active malignancy and recommend monitoring in patients with a history of childhood malignancy, particularly craniopharyngioma and leukemia, but do not contraindicate GH replacement in appropriately selected cancer survivors [63].

11.7 Mortality in critical illness

Two multicenter randomized controlled trials in critically ill patients (Takala et al. 1999) demonstrated significantly increased mortality in patients receiving high-dose GH (5.3 to 8 mg/day) compared to placebo [64]. The mechanism was not fully elucidated but was attributed to GH-mediated insulin resistance, hyperglycemia, and immunomodulatory effects in the context of sepsis and multiorgan failure. Somatropin is contraindicated in patients with acute critical illness.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five growth-promoting or GH-axis compounds against somatropin, evaluated against five competency standards: novelty, effect size, promising potential, side-effect profile, and overall validation. The five comparators were selected to span the principal alternative approaches to growth promotion and GH-axis modulation.

12.1 Somapacitan (Sogroya)

Mechanism: Albumin-binding GH analog. Somapacitan is a modified somatropin molecule with a single amino acid substitution (Leu101 to Cys101) and attachment of a C18 fatty acid chain through a linker to the introduced cysteine. The fatty acid binds reversibly to circulating albumin, reducing renal clearance and extending the elimination half-life to approximately 2 to 3 days, enabling weekly subcutaneous administration [12].

Novelty: Moderate. The albumin-binding fatty acid technology is adapted from the insulin analog (insulin degludec, insulin detemir) and GLP-1 agonist (semaglutide, liraglutide) programs at Novo Nordisk. Application to GH is novel but the platform is established.

Effect size: The REAL 3 pivotal trial (Johannsson et al. 2020) in 92 adult GHD patients demonstrated non-inferiority of weekly somapacitan to daily somatropin (Norditropin) on trunk fat percentage change over 34 weeks [12]. The REAL 4 pediatric trial (Engstrom et al. 2023) demonstrated non-inferiority in annualized height velocity in GHD children. Effect sizes are equivalent to daily somatropin by design.

Promising potential: High. Approved by FDA (2020 adult, 2023 pediatric). Weekly dosing improves adherence and patient preference. Positioned to capture substantial market share from daily somatropin.

Side-effect profile: Similar to daily somatropin. Injection-site reactions are more frequent owing to larger injection volumes. Anti-drug antibody formation has been observed but non-neutralizing in pivotal trials. No novel safety signals beyond the

daily somatropin profile.

Overall validation: High. Regulatory approval in both adult and pediatric GHD, supported by a comprehensive Phase 3 program.

Comparison to somatropin: Somapacitan is pharmacologically equivalent to somatropin with the operational advantage of weekly dosing. The underlying GH molecule is structurally modified; the albumin-binding extension does not alter receptor pharmacology but does produce a different pharmacokinetic profile (lower C_{max}, prolonged exposure). Somatropin retains the advantages of the longest clinical track record, lowest cost (biosimilar availability), and the largest safety database.

12.2 Lonapegsomatropin (Skytrofa)

Mechanism: Transient PEGylation prodrug of somatropin. Lonapegsomatropin consists of unmodified somatropin conjugated through a proprietary TransCon (transient conjugation) linker to a 40 kDa polyethylene glycol (PEG) carrier. The PEG carrier is inert and reduces renal clearance; the linker undergoes spontaneous hydrolysis at physiological pH and temperature, releasing unmodified somatropin with a sustained release half-life of approximately 25 hours [13].

Novelty: Moderate to high. The TransCon prodrug concept is novel in the GH space, and the release of fully unmodified somatropin distinguishes lonapegsomatropin from somapacitan (which is a structurally modified GH analog).

Effect size: The heiGHt trial (Thornton et al. 2021) in 161 treatment-naïve prepubertal GHD children demonstrated superiority of weekly lonapegsomatropin to daily somatropin (Genotropin) in annualized height velocity (11.2 vs 10.3 cm/year, $p = 0.009$) over 52 weeks [13]. The fliGHt trial confirmed sustained efficacy through 3 years.

Promising potential: High. FDA-approved for pediatric GHD (2021). The superiority finding (rather than non-inferiority alone) in the pivotal trial is a differentiating claim. Adult GHD approval is under regulatory review.

Side-effect profile: Similar to daily somatropin. PEG accumulation has been a theoretical concern for PEGylated biologics, but the TransCon design releases free PEG that is renally cleared. Anti-PEG antibody formation has not been reported as clinically significant. No novel safety signals.

Overall validation: High. FDA-approved for pediatric GHD with a superiority claim on the primary endpoint.

Comparison to somatropin: Lonapegsomatropin releases unmodified somatropin, making it the closest pharmacological equivalent to daily somatropin among the long-acting alternatives. The weekly dosing and superiority claim are advantages. Somatropin retains the advantages of the longest clinical track record, lowest cost, and broadest indication coverage.

12.3 Mecasermin (Increlex)

Mechanism: Recombinant human IGF-1. Mecasermin is the 70-amino acid IGF-1 polypeptide produced by recombinant DNA technology, acting directly through the IGF-1 receptor to promote growth without requiring GH receptor signaling [65]. It is indicated for severe primary IGF-1 deficiency (GH gene deletion, GH receptor defects such as Laron syndrome, post-GH receptor signaling defects) in which somatropin is ineffective because the defect is downstream of or at the level of the GH receptor.

Novelty: Low. IGF-1 as a growth-promoting agent has been investigated since the 1980s. The mechanism is well characterized.

Effect size: In patients with severe primary IGF-1 deficiency (the indicated population), mecasermin produces growth velocity increases from approximately 2 to 3 cm/year (untreated) to approximately 8 to 9 cm/year in the first year of treatment [65]. In patients with intact GH receptor signaling (the population treated with somatropin), mecasermin is not indicated and would produce additive IGF-1 effects without the direct metabolic effects of GH.

Promising potential: Low. The indicated population (severe primary IGF-1 deficiency) is extremely small (estimated 1,000 to 3,000 patients worldwide). The compound is not positioned to replace somatropin in GH-responsive populations.

Side-effect profile: Hypoglycemia is the principal safety concern (IGF-1 has insulin-like hypoglycemic activity), requiring administration with meals. Intracranial hypertension, lymphoid tissue hypertrophy (tonsillar and adenoidal), and lipohypertrophy at injection sites are reported [65].

Overall validation: Moderate. FDA-approved (2005) for severe primary IGF-1 deficiency. Limited clinical experience owing to the rare indication.

Comparison to somatropin: Mecasermin and somatropin act at different points in the GH-IGF-1 axis. Mecasermin is indicated only when somatropin is ineffective (GH resistance). The compounds are complementary, not competitive, in clinical positioning.

12.4 Tesamorelin (Egrifta)

Mechanism: Synthetic analog of growth hormone-releasing hormone (GHRH). Tesamorelin is a 44-amino acid peptide identical to endogenous GHRH(1-44) with an N-terminal trans-3-hexenoic acid modification that confers resistance to dipeptidyl peptidase IV cleavage [66]. It stimulates endogenous GH secretion from pituitary somatotrophs and is approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients.

Novelty: Low to moderate. GHRH analogs have been investigated since the 1980s. Tesamorelin is the only approved GHRH analog.

Effect size: The pivotal trials (Falutz et al. 2007, 2010) demonstrated significant reduction in visceral adipose tissue (approximately 15 to 18 percent reduction) in HIV-associated lipodystrophy [66]. The compound does not produce clinically meaningful linear growth in children and is not indicated for growth failure.

Promising potential: Moderate. FDA-approved for a niche indication. Investigation in age-related cognitive decline and visceral adiposity in non-HIV populations is ongoing. The compound does not substitute for somatropin in GH deficiency because it requires functional pituitary somatotrophs.

Side-effect profile: Injection site reactions (erythema, pruritus), arthralgia, peripheral edema. Fluid-retention side effects are milder than with somatropin because tesamorelin produces physiological pulsatile GH secretion rather than sustained exogenous GH exposure.

Overall validation: Moderate. FDA-approved for a single niche indication with robust clinical data in that population.

Comparison to somatropin: Tesamorelin stimulates endogenous GH secretion and is therefore only effective in patients with intact pituitary function. Somatropin replaces GH directly and is effective regardless of pituitary status. The compounds

have non-overlapping primary indications. Tesamorelin produces a more physiological pulsatile GH pattern than exogenous somatropin, which is a theoretical advantage for metabolic and hepatic gene-expression outcomes.

12.5 Pegvisomant (Somavert)

Mechanism: GH receptor antagonist. Pegvisomant is a PEGylated GH analog with mutations in the Site 2 binding region that prevent productive GHR dimerization. The compound binds GHR through Site 1 but blocks the conformational activation required for JAK2 transphosphorylation, producing functional GHR antagonism and dose-dependent reduction in serum IGF-1 [67]. It is approved for acromegaly (GH excess).

Novelty: High. Pegvisomant is the only approved GH receptor antagonist and represents a unique pharmacological mechanism in the GH-IGF-1 axis.

Effect size: Pegvisomant normalizes serum IGF-1 in approximately 90 percent of acromegaly patients at optimized doses (10 to 30 mg/day subcutaneously), a higher normalization rate than somatostatin analogs (approximately 50 to 60 percent) [67].

Promising potential: Moderate. Approved for acromegaly (2003). Not applicable for growth promotion (the compound inhibits GH action).

Side-effect profile: Injection-site reactions, elevated hepatic transaminases (rare), and tumor growth monitoring in acromegaly patients. The compound does not produce the insulin resistance or sodium retention of somatropin because it inhibits rather than activates GH signaling.

Overall validation: High. FDA-approved for acromegaly with extensive clinical experience.

Comparison to somatropin: Pegvisomant and somatropin are pharmacological opposites: somatropin activates the GHR and pegvisomant antagonizes it. The comparison is instructive for understanding the GH-IGF-1 axis: the opposing clinical profiles of somatropin (for GH deficiency) and pegvisomant (for GH excess) validate the central role of GHR signaling in human physiology. The compounds are not alternatives for any shared indication.

12.6 Comparator summary

The five comparators span the GH-IGF-1 axis at distinct intervention points. **Somapacitan** and **lonapegsomatropin** are long-acting alternatives to daily somatropin that are pharmacologically equivalent or superior (lonapegsomatropin, superiority claim) to daily somatropin with the operational advantage of weekly administration. **Mecasermin** acts downstream of the GH receptor at the IGF-1 receptor and is indicated only when the GH receptor is non-functional. **Tesamorelin** acts upstream at the pituitary to stimulate endogenous GH secretion and is indicated only in the presence of functional somatotrophs. **Pegvisomant** is a GH receptor antagonist indicated for GH excess and serves as a pharmacological complement to somatropin.

Somatropin occupies the central position in this landscape as the direct GH replacement therapy with the longest clinical track record (more than 35 years of post-approval use), the broadest indication coverage (more than 10 approved indications), the largest safety database (more than 100,000 patient-years in multinational registries), and the lowest cost (biosimilar availability). The principal competitive pressure comes from the weekly long-acting formulations (somapacitan, lonapegsomatropin), which offer equivalent or superior efficacy with improved convenience. The long-acting formulations are unlikely to fully displace daily somatropin in the near term owing to cost differentials, the absence of some indication approvals, and the established treatment patterns with daily injection.

Investigators considering growth-promoting agents for research applications should recognize that somatropin remains the reference standard against which all GH-axis interventions are compared. The extensive clinical literature, well-characterized pharmacology, regulatory approval history, and biosimilar availability make somatropin the most operationally accessible and scientifically validated compound for GH replacement and growth promotion research.

13. References

1. Goeddel DV, Heyneker HL, Hozumi T, et al. Direct expression in *Escherichia coli* of a DNA sequence coding for human growth hormone. *Nature*. 1979;281(5732):544-548.
2. Koch TK, Berg BO, De Armond SJ, Gravina RF. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism: possible relation to the administration of cadaveric human growth hormone. *N Engl J Med*. 1985;313(12):731-733.
3. Brown P, Brandel JP, Sato T, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. *Emerg Infect Dis*. 2012;18(6):901-907.
4. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science*. 1992;255(5042):306-312.
5. Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. *Oncogene*. 2000;19(21):2585-2597.
6. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. *Endocr Rev*. 2001;22(1):53-74.
7. Laursen T, Jorgensen JO, Christiansen JS. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen. *Clin Endocrinol (Oxf)*. 1994;40(3):373-378.
8. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants and children. *N Engl J Med*. 2003;349(12):1157-1167.
9. Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. *Eur J Endocrinol*. 2016;174(2):P1-P9.
10. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96(6):1587-1609.

11. Ho KKY; 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II. *Eur J Endocrinol.* 2007;157(6):695-700.
12. Johannsson G, Gordon MB, Hojby Rasmussen M, et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. *J Clin Endocrinol Metab.* 2020;105(4):e1358-e1376.
13. Thornton PS, Maniatis AK, Engstrom K, et al. Weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency: the phase 3 heiGHt trial. *J Clin Endocrinol Metab.* 2021;106(11):3184-3195.
14. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. *Lancet.* 2000;355(9204):610-613.
15. Ranke MB, Lindberg A; KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. *J Clin Endocrinol Metab.* 2010;95(3):1229-1237.
16. Abs R, Bengtsson BA, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. *Clin Endocrinol (Oxf).* 1999;50(6):703-713.
17. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. *J Clin Endocrinol Metab.* 2010;95(1):167-177.
18. Cronin MJ. Pioneering recombinant growth hormone manufacturing: decades later, a technological landmark in biotechnology. *Drug Dev Res.* 1997;41(3-4):131-138.
19. Bewley TA, Li CH. The chemistry and conformation of human pituitary growth hormone. *Adv Enzymol Relat Areas Mol Biol.* 1975;42:73-166.
20. Ultsch MH, Somers W, Kossiakoff AA, De Vos AM. The crystal structure of affinity-matured human growth hormone at 2 Å resolution. *J Mol Biol.* 1994;236(1):286-299.
21. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. *Endocr Rev.* 1991;12(4):424-449.

22. Pavlovic M, Girardin E, Kapetanovic L, Ho K, Trouvin JH. Similar biological medicinal products containing recombinant human growth hormone: European regulation. *Horm Res.* 2008;69(1):14-21.
23. Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. *Mol Endocrinol.* 2006;20(11):2613-2629.
24. Holt RI, Sonksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. *Br J Pharmacol.* 2008;154(3):542-556.
25. Li CH, Papkoff H. Preparation and properties of growth hormone from human and monkey pituitary glands. *Science.* 1956;124(3235):1293-1294.
26. Raben MS. Treatment of a pituitary dwarf with human growth hormone. *J Clin Endocrinol Metab.* 1958;18(8):901-903.
27. Kaplan SL, Underwood LE, August GP, et al. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. *Lancet.* 1986;1(8483):697-700.
28. Bentley R. Clinical trial results with the biosimilar somatropin Omnitrope. *Horm Res.* 2008;69(Suppl 1):31-36.
29. Brooks AJ, Dai W, O'Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. *Science.* 2014;344(6185):1249783.
30. Frank SJ. Classical and novel GH receptor signaling pathways. *Mol Cell Endocrinol.* 2020;518:110999.
31. Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. *N Engl J Med.* 2003;349(12):1139-1147.
32. Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. *Endocr Rev.* 1987;8(4):426-438.
33. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. *Endocr Rev.* 2009;30(2):152-177.
34. Greenhalgh CJ, Rico-Bautista E, Lober M, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. *J Clin Invest.* 2005;115(2):397-406.

35. Waxman DJ. Growth hormone pulse-activated STAT5 signalling: a unique regulatory mechanism governing sexual dimorphism of liver gene expression. *Novartis Found Symp.* 2000;227:61-74.
36. Baumann G, Shaw MA, Amburn K. Regulation of plasma growth hormone-binding proteins in health and disease. *Metabolism.* 1989;38(7):683-689.
37. Schwartzbauer G, Bhatt H, Gress RE, et al. Renal and hepatic clearance of growth hormone. *Endocrinology.* 1987;120(6):2273-2280.
38. Greenspan FS, Li CH, Simpson ME, Evans HM. Bioassay of hypophyseal growth hormone: the tibia test. *Endocrinology.* 1949;45(5):455-463.
39. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. *Proc Natl Acad Sci U S A.* 1999;96(13):7324-7329.
40. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. *Endocr Rev.* 2008;29(5):535-559.
41. Kelley KW, Weigent DA, Kooijman R. Protein hormones and immunity. *Brain Behav Immun.* 2007;21(4):384-392.
42. Colao A, Di Somma C, Rota F, et al. Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restart. *J Clin Endocrinol Metab.* 2005;90(5):2659-2665.
43. Ranke MB, Lindberg A, Chatelain P, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. *J Clin Endocrinol Metab.* 1999;84(4):1174-1183.
44. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. *J Clin Endocrinol Metab.* 1996;81(5):1704-1710.
45. Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. *J Pediatr.* 1998;132(2):319-324.
46. Deal CL, Tony M, Hoybye C, et al. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. *J Clin Endocrinol Metab.* 2013;98(6):E1072-

E1087.

47. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. *J Clin Endocrinol Metab.* 2007;92(3):804-810.
48. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. *J Clin Endocrinol Metab.* 2007;92(4):1442-1445.
49. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. *J Clin Endocrinol Metab.* 2004;89(5):2192-2199.
50. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. *Ann Intern Med.* 1996;125(11):873-882.
51. Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. *Ann Surg.* 2005;242(5):655-661.
52. Leschek EW, Rose SR, Yanovski JA, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. *J Clin Endocrinol Metab.* 2004;89(7):3140-3148.
53. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. *N Engl J Med.* 1990;323(1):1-6.
54. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med.* 2007;146(2):104-115.
55. Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. *Nat Rev Endocrinol.* 2013;9(5):265-276.
56. Porretti S, Giavoli C, Ronchi C, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T4 therapy become mandatory? *J Clin Endocrinol Metab.*

2002;87(5):2042-2045.

57. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. *Endocr Rev.* 2004;25(5):693-721.
58. Blum RA, Mair S, Engstrom K. Pharmacokinetic interaction study of lonapeg-somatropin with cytochrome P450 substrates in adult subjects with growth hormone deficiency. *Clin Pharmacol Drug Dev.* 2022;11(5):619-627.
59. Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. *N Engl J Med.* 1993;329(9):665-666.
60. Gkourogianni A, Andrew M, Engstrom K, et al. Clinical characterization of patients with slipped capital femoral epiphysis in the National Cooperative Growth Study. *Horm Res Paediatr.* 2020;93(5):293-300.
61. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. *J Clin Endocrinol Metab.* 2012;97(2):416-425.
62. Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, the Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. *J Clin Endocrinol Metab.* 2012;97(2):E213-E217.
63. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. *J Clin Endocrinol Metab.* 2002;87(7):3136-3141.
64. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. *N Engl J Med.* 1999;341(11):785-792.
65. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. *J Clin Endocrinol Metab.* 2007;92(3):902-910.

66. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. *N Engl J Med.* 2007;357(23):2359-2370.
67. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. *N Engl J Med.* 2000;342(16):1171-1177.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Somatropin is approved by the United States Food and Drug Administration and by the European Medicines Agency for multiple indications as described in the clinical evidence base section. Investigators conducting research outside of approved indications should consult their local regulatory authority and institutional review board before any human research application.